MaxCyte (LSE:MXCT) Common Stock : £0.82 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is MaxCyte Common Stock?

MaxCyte's quarterly common stock declined from Sep. 2023 (£0.84 Mil) to Dec. 2023 (£0.82 Mil) but then stayed the same from Dec. 2023 (£0.82 Mil) to Mar. 2024 (£0.82 Mil).

MaxCyte's annual common stock increased from Dec. 2021 (£0.76 Mil) to Dec. 2022 (£0.84 Mil) but then declined from Dec. 2022 (£0.84 Mil) to Dec. 2023 (£0.82 Mil).

MaxCyte Common Stock Historical Data

The historical data trend for MaxCyte's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Common Stock Chart

MaxCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.44

0.58

0.76

0.84

0.82

MaxCyte Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.85	0.82	0.84	0.82	0.82

MaxCyte Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

MaxCyte (LSE:MXCT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

MXCT:USA MYE0:Germany

Address

9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850

Website

https://www.maxcyte.com

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.